Treating menopause—MHT and beyond

SR Davis, RJ Baber - Nature Reviews Endocrinology, 2022‏ - nature.com
Every woman who lives past midlife will experience menopause, which, by definition, is
complete cessation of ovarian function. This process might occur spontaneously (natural …

The menopause transition: signs, symptoms, and management options

N Santoro, C Roeca, BA Peters… - The Journal of Clinical …, 2021‏ - academic.oup.com
Context Menopause, the permanent cessation of menses, reflects oocyte depletion and loss
of gonadal steroids. It is preceded by a transition state, the perimenopause, which is …

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

S Lederman, FD Ottery, A Cano, N Santoro, M Shapiro… - The Lancet, 2023‏ - thelancet.com
Background Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the
treatment of vasomotor symptoms in menopausal women as options are scarce for those …

Drug repurposing: progress, challenges and recommendations

S Pushpakom, F Iorio, PA Eyers, KJ Escott… - Nature reviews Drug …, 2019‏ - nature.com
Given the high attrition rates, substantial costs and slow pace of new drug discovery and
development, repurposing of'old'drugs to treat both common and rare diseases is …

[HTML][HTML] Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial

G Neal-Perry, A Cano, S Lederman… - Obstetrics & …, 2023‏ - journals.lww.com
OBJECTIVE: To evaluate the safety, tolerability, and effect of fezolinetant on endometrial
health over 52 weeks. METHODS: We conducted a phase 3, randomized, double-blind, 52 …

Hormones and aging: an endocrine society scientific statement

AR Cappola, RJ Auchus… - The Journal of …, 2023‏ - academic.oup.com
Multiple changes occur across various endocrine systems as an individual ages. The
understanding of the factors that cause age-related changes and how they should be …

Hormone therapy in menopause: concepts, controversies, and approach to treatment

VA Flores, L Pal, JAE Manson - Endocrine reviews, 2021‏ - academic.oup.com
Hormone therapy (HT) is an effective treatment for menopausal symptoms, including
vasomotor symptoms and genitourinary syndrome of menopause. Randomized trials also …

Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials

JAV Pinkerton, JA Simon, H Joffe, PM Maki, RE Nappi… - JAMa, 2024‏ - jamanetwork.com
Importance Safe and effective nonhormonal treatments for menopausal vasomotor
symptoms (VMS) are needed. Objective To evaluate the efficacy and safety of elinzanetant …

[HTML][HTML] Efficacy and safety of elinzanetant, a selective neurokinin-1, 3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

JA Simon, RA Anderson, E Ballantyne, J Bolognese… - Menopause, 2023‏ - journals.lww.com
Objective Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of
vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This …

The emerging therapeutic potential of kisspeptin and neurokinin B

B Patel, K Koysombat, EG Mills, J Tsoutsouki… - Endocrine …, 2024‏ - academic.oup.com
Kisspeptin (KP) and neurokinin B (NKB) are neuropeptides that govern the reproductive
endocrine axis through regulating hypothalamic gonadotropin-releasing hormone (GnRH) …